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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent
of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to
cause severe disease manifestations in the lungs. Although COVID-19 has been
extensively characterized clinically, the factors distinguishing SARS-CoV-2 from other
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respiratory viruses are unknown. Here, we compared the clinical, histopathological, and
immunological characteristics of patients with COVID-19 and pandemic influenza A
(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue
injury markers, and a histological pattern of alveolar pneumonia in pandemic influenza A
(H1N1) patients. Conversely, dry cough, gastrointestinal symptoms and interstitial lung
pathology were observed in COVID-19 cases. Pandemic influenza A(H1N1) was
characterized by higher levels of IL-1RA, TNF-a, CCL3, G-CSF, APRIL, sTNF-R1,
sTNF-R2, sCD30, and sCD163. Meanwhile, COVID-19 displayed an immune profile
distinguished by increased Th1 (IL-12, IFN-g) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine
levels, along with IL-1b, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3. Our
data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory
response that is different from the immune response against pandemic influenza A
(H1N1). Furthermore, we demonstrated the diagnostic potential of some clinical and
immune factors to differentiate both diseases. These findings might be relevant for the
ongoing and future influenza seasons in the Northern Hemisphere, which are historically
unique due to their convergence with the COVID-19 pandemic.
Keywords: SARS-CoV-2, COVID-19, Influenza A(H1N1) pdm09, pandemic influenza, acute respiratory
distress syndrome
INTRODUCTION
The novel SARS-CoV-2 has submerged the world into a public
health crisis of unprecedented features. With more than 113.4
million infected people and 2.5 million deaths, SARS-CoV-2
continues spreading worldwide (1). Although other emerging
pathogens have caused similar outbreaks in the past, the
pandemic influenza A(H1N1) pdm09 virus is the immediate
antecedent reference for the global spread of a new zoonotic
respiratory pathogen. This virus emerged in Mexico in 2009,
causing approximately 151,700-575,400 deaths worldwide during
the first year after its appearance (2–4). Ever since, the influenza A
(H1N1) pdm09 virus has continued circulating globally, acquiring
a seasonal transmission pattern (5). Notably, the emergence of
SARS-CoV-2 in December of 2019 (6–8), occurred when several
countries were at the peak of the flu season. This hampered
differentiating COVID-19 and influenza during the early days of
the current pandemic. With improved understanding of the
clinical characteristics and pathobiology of COVID-19 (9–12),
the overall identification of positive cases drastically improved.
Despite this, only a few comparisons of the characteristics of
COVID-19 and influenza have been conducted (13–16). This is
crucial as both entities are converging at several regions of the
Northern hemisphere. In this context, the accurate identification
of the causative pathogen has important therapeutic
implications, including the selection of adequate antiviral
drugs. A better understanding of the host factors implicated in
protective vs. pathogenic immunity against SARS-CoV-2 is also
crucial to guide immunotherapeutic interventions for patients in
critical conditions. Unfortunately, what we currently
comprehend about the immunopathology of severe COVID-19
is a paradox: the adaptive response is overactive but unable to
control the virus. In fact, patients with COVID-19 display a pro-
inflammatory (IL-1b, IL-6, IL-7, IL-8, IL-9, FGF, G-CSF, GM-
CSF, IFN-ɣ, CXCL10, CCL2, CCL3, CCL4, PDGF, TNFa, and
VEGF) and regulatory cytokine profile (IL-10 and TGFb;
cytokine storm) (17, 18). Interestingly, unlike other cytokine
storm syndromes, the polyfunctional immune activation of
COVID-19 is accompanied by lymphopenia, reduced T cell
numbers, and strong infiltration of immune cells into the lung
(19–21). Thus, the lung damage associated with COVID-19 may
be caused both by the virus and hyperinflammation.
Comparing the immune profiles of COVID-19 with other
respiratory pathogens may dissipate prevailing controversies about
the immunopathology of SARS-CoV-2 infection. For this reason,
here we evaluated clinical and immunological factors distinguishing
critically ill COVID-19 and pandemic influenza A(H1N1) patients.
We also compared histopathological changes and expression of
immune markers in the lungs of patients with both diseases. Our
results reveal crucial differences in the clinical characteristics of the
two infections. Furthermore, our analyses clearly show that the
human immune response elicited after SARS-CoV-2 is completely
different from the immune responses against the influenza A
(H1N1) pdm09 virus. Our study may support the use of some of




We conducted a prospective cohort study in patients with an
acute respiratory illness that attended the emergency department
of the Instituto Nacional de Ciencias Médicas y Nutrición
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Salvador Zubirán (INCMNSZ), and the Instituto Nacional de
Enfermedades Respiratorias Ismael Cosıó Villegas (INER) in
Mexico City. Individuals with laboratory-confirmed COVID-19
requiring hospital admission were eligible. Detection of SARS-
CoV-2 was performed by real-time polymerase chain reaction
(RT-PCR) in swab samples, bronchial aspirates (BA), or
bronchoalveolar lavage (BAL) specimens, as previously
described (22). Briefly, viral RNA was extracted from clinical
samples with the MagNA Pure 96 system (Roche, Penzberg,
Germany). The RT-PCR reactions were performed in a total
volume of 25mL, containing 5mL of RNA, 12.5mL of 2 × reaction
buffer provided with the Superscript III one-step RT-PCR system
with Platinum Taq Polymerase (Invitrogen, Darmstadt,
Germany; containing 0.4 mM of each deoxyribose
triphosphates (dNTP) and 3.2 mM magnesium sulfate), 1mL of
reverse transcriptase/Taq mixture from the kit, 0.4mL of a 50 mM
magnesium sulfate solution (Invitrogen), and 1mg of
nonacetylated bovine serum albumin (Roche). Primer and
probe sequences, as well as optimized concentrations, are
shown in Supplemental Table 1. All oligonucleotides were
synthesized and provided by Tib-Molbiol (Berlin, Germany).
Thermal cycling was performed at 55°C for 10 min for reverse
transcription, followed by 95°C for 3 min and then 45 cycles of
95°C for 15 s, 58°C for 30 s.
Individuals with COVID-19 were further categorized into two
groups: a) moderate COVID-19 group (n=10), that included
patients with respiratory symptoms that did not require
mechanical ventilation (MV); and b) severe COVID-19 group
(n=24), consisting of patients requiring invasive MV and
admission to the intensive care unit (ICU). Our comparative
cohort included patients with influenza-like illness (ILI) that
attended to the INER in Mexico City during the immediately
preceding 2019/2020 flu season. Individuals with confirmed
influenza A(H1N1) pdm09 virus infection that progressed to
acute respiratory distress syndrome (ARDS), requiring MV and
admission to the ICU were included. ILI was defined as an acute
respiratory illness with a measured temperature of ≥ 38°C and
cough, with onset within the past ten days. These subjects were first
screened for influenza A virus infection using the Fuji dri-chem
immuno AG cartridge FluAB kit (Fujifilm Corp, Tokyo, Japan)
rapid influenza diagnostic test (RIDT) in fresh respiratory swab
specimens. In positive cases, further molecular characterization of
the causative influenza A virus subtype was assessed by RT-PCR.
All influenza cases enrolled in the study were infected with the
pandemic influenza A(H1N1) pdm09 virus. None of the
participants had human immunodeficiency virus (HIV) infection.
Data Retrieval
Microsoft Excel (MS Excel 365) was used for data collection.
Clinical and demographic data were retrieved from all
participants´ medical records. These data included age, gender,
anthropometrics, comorbidities, symptoms, triage vital signs, the
severity of illness scores at admission [Sequential Organ Failure
Assessment (SOFA), and Acute Physiology And Chronic Health
Evaluation II (APACHE II)], and initial laboratory tests. Initial
laboratory tests were defined as the first test results available
(typically within 24 hours of admission) and included white
blood cell counts, liver and kidney function, gasometric
parameters at admission, and other tissue-injury biomarkers.
Cytokine Determinations
Peripheral blood samples were obtained from all participants at
hospital admission. Serum levels of different cytokines,
chemokines, growth factors, and other immune mediators were
determined by Luminex assays using the Luminex platform Bio-
Plex Multiplex 200 (Bio-Rad Laboratories, Inc., Hercules, CA,
USA). Serum samples from 13 healthy donors were used as
controls. The immune mediators that were quantified are listed
as follows: IFN-a, interferon-alpha, IFN-b; interferon-beta; IFN-g,
interferon-gamma; TNF-a, tumor necrosis factor-alpha; IL-1b,
interleukin 1beta; IL-1RA, interleukin 1 receptor antagonist;
IL-2, interleukin 2; IL-4, interleukin 4; IL-5, interleukin 5; IL-6,
interleukin 6; IL-7, interleukin 7; IL-8, interleukin 8; IL-9,
interleukin 9; IL-10, interleukin 10; IL-12 (p40), interleukin 12
p40 subunit; IL-12p70, interleukin 12 p70 subunit; IL-13,
interleukin 13; IL-15, interleukin 15; IL-17A, interleukin 17A;
IL-26, interleukin 26; IL-32, interleukin 32; CXCL10, C-X-C
motif chemokine ligand 10, CCL2, C-C motif chemokine
ligand 2; CCL3, C-C motif chemokine ligand 3; CCL4, C-C
motif chemokine ligand 4; CCL5, C-C motif chemokine ligand 5;
CCL11, C-C motif chemokine ligand 11; G-CSF, granulocyte
colony-stimulating factor; bFGF, basic fibroblast growth factor;
PDGF-BB, platelet-derived growth factor bb; VEGF, vascular
endothelial growth factor; APRIL/TNFSF13, A proliferation-
inducing ligand/tumor necrosis factor ligand superfamily member
13; BAFF/TNFSF13B, B-cell activating factor/tumor necrosis factor
ligand superfamily member 13B; sCD30/TNFRSF8, soluble CD30/
tumor necrosis factor ligand superfamily member 8; sCD163,
soluble CD163; chitinase 3/like1; gp130/sIL-6Rb, glycoprotein of
130 kDa/soluble IL-6 receptor beta; sIL-6Ra, soluble IL-6 receptor
alpha; MMP-1, matrix metalloprotease 1; MMP-2, matrix
metalloprotease 2; MMP-3, matrix metalloprotease 3; osteocalcin;
ostepontin; pentraxin-3; sTNF-R1, soluble tumor necrosis factor
receptor 1; sTNF-R2, soluble tumor necrosis factor receptor 2;
TSLP, thymic stromal lymphopoietin; TWEAK/TNFSF12, tumor
necrosis factor-like weak inducer of apoptosis/tumor necrosis factor
ligand superfamily member 12.
Histopathological Analysis
Formalin-fixed and paraffin-embedded lung autopsy specimens
from patients who died of pandemic influenza A(H1N1) or
COVID-19 (N=2 patients per group) were obtained from the
Pathology Department of the INER. Sections of 3-5mm were
processed for hematoxylin-eosin (H&E) staining for
histopathological analysis. For immunohistochemistry (IHQ),
lung sections were mounted on silane-covered slides,
deparaffinized in xylenes, and hydrated with a series of graded
alcohol-to-water dilutions. The endogenous peroxidase was
blocked with 3% hydrogen peroxide for 30 minutes. Sections
were incubated overnight at room temperature with optimal
dilutions (1:100) of the following antibodies: anti-IFN-g (Anti-
Interferon gamma antibody, ab9657, Abcam, UK), anti-IL-1b
(IL-1b Antibody (H-153): sc-7884, Santa Cruz Biotechnology
Inc., Santa Cruz, CA), anti-IL-4 (IL-4 Antibody (OX81):
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sc-53084, Santa Cruz Biotechnology Inc., Santa Cruz, CA), and
anti-IL-17A (Anti-IL-17 antibody (ab91649), Abcam, UK).
Secondary biotinylated antibodies labeled with peroxidase were
added, and those attached were revealed with diaminobenzidine
(DAB) for 5 minutes (MACH 1 Universal HRP-Polymer
Detection Kit, Biocare Medical, LLC). Slides were counter-
stained with hematoxylin.
Statistical Analysis
Descriptive statistics were used to characterize the study population
clinically. Frequencies and proportions were calculated for
categorical data. Means, medians, standard deviations (SD),
interquartile ranges (IQR), and 95% confidence intervals were
used for continuous variables. Differences between groups were
assessed by the Fisher exact, Chi-square test, Mann-Whitney U test,
or Kruskal-Wallis test with post hoc Dunn´s test, as appropriate.
Multiple linear regression analyses using Spearman rank correlation
coefficients were used to determine correlations between continuous
variables. ROC curves were constructed to estimate the diagnostic
utility of different variables to differentiate between participant
groups in terms of their area under the curve (AUC). The
prognostic value of the different clinical and immunological
parameters expressed in terms of odds ratio (OR) values for
adverse outcomes (intubation, death) was estimated using
binomial logistic regression analyses.
Principal component analyses (PCAs) were conducted to
analyze how the study participants clustered together according
to the interplay between their clinical and immunological
characteristics. Furthermore, a Linear Discriminant Analysis
(LDA) without and with “leave-one-out” type cross-validation
was performed to assess whether the linear combination of
different variables allowed differentiating individuals according
to their diagnosis. The variables included were AST, ALT, LDH,
ALP, procalcitonin, SOFA, IL-1b, IL-1RA, IL-2, IL-4, IL-5, IL-7,
IL-12, IL-13, IL- 17A, TNF-a, CCL3, CCL11, G-CSF, and VEGF.
A Wilks ‘Lambda test was performed to evaluate the
discriminatory power of each variable in the LDA. Variables
were transformed to log10 to meet the LDA assumptions and
were scaled to prevent the scale of each variable from influencing
the analysis results. Individuals with missing data were omitted
from PCA and LDA analyses. All analyses were conducted using
GraphPad Prism 8 (La Jolla, CA), R Statistical Software
(Foundation for Statistical Computing, Vienna, Austria)
packages Factoextra and MASS, and Python packages pandas
v0.23.4 and seaborn v0.10.1. Specific analysis tests are also
mentioned in figure legends. P values ≤0.05 were considered as
significant: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
Study Approval
The Institutional Review Boards of the INCMNSZ (approval
number: 3349) and the INER (approval number: B28-16 and B09-
20) inMexico City approved the study. All participants or their legal
guardians providedwritten informed consent in accordancewith the
Declaration of Helsinki for Human Research. Clinical samples were
managed according to the Mexican Constitution law NOM-012-




The main demographic characteristics of enrolled patients were
similar (Table 1), although the proportion of males tended to be
higher in both groups of COVID-19 subjects, as reported before
(9, 11, 12, 17, 23, 24). Obesity was more frequent in pandemic
influenza A(H1N1) patients, whereas other comorbidities
(diabetes, systemic arterial hypertension (SAH), chronic
obstructive pulmonary disease (COPD), and obstructive sleep
apnea syndrome (OSA)) were equally distributed across groups.
Fever was the most frequent symptom among all participants,
followed by cough, fatigue, myalgia, arthralgia, and headache.
Dyspnea occurred in 10% of patients with moderate COVID-19
and in ~80% of individuals with severe COVID-19 and pandemic
influenza A(H1N1). Rhinorrhea, sore throat, thoracic pain, and
sputum production were more common during pandemic
influenza A(H1N1), whereas dry cough, diarrhea, and vomit
were more frequent among COVID-19 patients. This finding
suggests that some symptoms could differentiate these infectious
entities. We performed a logistic regression analysis with the
symptoms reported by pandemic influenza A(H1N1) and
COVID-19 patients at hospital admission. Fever and rhinorrhea
were associated with pandemic influenza A(H1N1), whereas dry
cough predicted COVID-19 (Supplemental Figure 1 and
Supplemental Table 2). Sore throat and thoracic pain were
marginally associated with pandemic influenza A(H1N1) but
did not reach statistical significance. Similarly, gastrointestinal
symptoms exhibited higher, but not significant odds ratio (OR)
values for COVID-19 (Supplemental Figure 1 and Supplemental
Table 2). Overall, patients in the moderate COVID-19 group
attended earlier after symptoms onset than individuals with severe
pandemic influenza A(H1N1) and COVID-19 (Table 1).
Laboratory Parameters of Pandemic
Influenza A(H1N1) and COVID-19
White blood cells (WBC), neutrophil counts, neutrophil to
lymphocyte ratio (NLR), glucose, total bilirubin, and aspartate
aminotransferase (AST) levels were similar in both pandemic
influenza A(H1N1) and severe COVID-19 groups, but lower in
the moderate COVID-19 group (Table 2). Low lymphocyte
counts were observed among all participants, indicating that
lymphopenia is not a unique feature of severe COVID-19. Renal
function parameters did not differ between groups. However,
levels of some tissue injury markers, such as alkaline phosphatase
(ALP), alanine aminotransferase (ALT), lactate dehydrogenase
(LDH), creatine phosphokinase (CPK), and procalcitonin, were
higher in pandemic influenza A(H1N1) as compared to COVID-
19 patients. We also observed that the SOFA and APACHE II
scores were higher in pandemic influenza A(H1N1) patients.
Importantly, both groups presented similar rates of
complications, and received equal supportive medical
interventions (Table 3). Despite this, the mortality of our
cohort of critically ill pandemic influenza A(H1N1) patients
was significantly lower (21%) than the mortality of severely ill
COVID-19 patients (62%). No fatality cases were observed in the
group of moderated COVID-19.
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Immune Profiles of Pandemic Influenza A
(H1N1) and COVID-19 Patients
The severity of pandemic influenza A(H1N1) and COVID-19 has
been systematically attributed to an exacerbated production of
pro-inflammatory cytokines (cytokine storm syndrome (CSS))
(25, 26). More recently, some researchers have also proposed that
immune depression, rather than an exuberant immune activation,
is responsible for the clinical pathology of severe COVID-19 (27).
Comparing the immune responses elicited by SARS-CoV-2
and influenza A(H1N1) pdm09 virus may be more helpful
in identifying unique immune mechanisms associated with
morbidity and mortality in COVID-19. Thus, we determined
the circulating levels of several immune mediators in pandemic
influenza A(H1N1) and COVID-19 patients. Also, we correlated
cytokine levels with clinical findings and disease outcomes. Our
results showed that critically ill COVID-19 patients had increased
serum levels of IL-1b, IL-1RA, IL-6, IL-9, and CXCL10, and lower
levels of IL-2 and IL17A as compared to healthy volunteer donors
(Figure 1 and Supplemental Figure 2). These findings are
coincident with the immune profiles that were reported in
Chinese patients with COVID-19 (9, 17, 28). Levels of pro-
inflammatory (IFN-g, IL-1b, IL-6, IL-9, IL-12p70, CCL11) and
anti-inflammatory (IL-4, IL-5, IL-10, IL-13) cytokines, as well
as VEGF, were higher in severely ill COVID-19 patients as
compared to pandemic influenza A(H1N1) subjects. In
contrast, levels of IL-1RA, IL-2, TNF-a, CCL3, and G-CSF were
more increased among pandemic influenza A(H1N1) patients
(Figure 1 and Supplemental Figure 2).
These serum cytokine profiles indicate that, besides a higher
production of pro-inflammatory and Th1 cytokines, SARS-CoV-
2, but not influenza A(H1N1) pdm09 infection, parallelly
induces Th2 responses. This may suggest that a lack of
sufficient regulation and balancing of the type of immune
response triggered after SARS-CoV-2 infection might
TABLE 1 | Clinical characteristics of patients with COVID-19 and pandemic influenza.






























































































































































































Illness onset - hospital admission (days) 7 (4 - 8.5) 0.0583 3 (0 – 5.7) 0.0158 6 (5 – 13.2) >0.9999





37 (36.8 – 37)
26 (22 – 30)
93 (80 – 103)





36.5 (36.3 – 37.2)
20 (16.7 – 21.7)
90 (75.7 – 99.7)





37 (37 – 37.7)
24 (22 – 26)
84 (72 – 90)





Data are displayed as n (%) or median (IQR). N is the total number of patients with available data. BMI, body mass index; bpm, breaths/beats per minute; COPD, chronic obstructive
pulmonary disease; IQR, interquartile range; ICU, intensive care unit; MAP, mean arterial pressure; OSA, obstructive sleep apnea syndrome; SAH, systemic arterial hypertension; SD,
standard deviation. Differences in continuous variables were estimated using the Kruskal Wallis with post hoc Dunn´s test. Differences in categorical variables were calculated using the
Fisher’s exact or the Chi-square test as appropriate.
Choreño-Parra et al. COVID-19 and Pandemic Influenza A(H1N1)
Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 5935955
contribute to the immune dysfunction reported during COVID-
19. Also, the proinflammatory and profibrotic immune profile
observed in COVID-19 patients may contribute to the extensive
tissue damage and poor outcomes reported during SARS-CoV-2
infection (27, 29). Other cytokines similarly increased in patients
with severe pandemic influenza A(H1N1) and COVID-19
included IL-7, IL-15, IL8, and CXCL10 (Supplemental
Figure 2).
Histopathological Characteristics of the
Lungs of Pandemic Influenza A(H1N1) and
COVID-19 Patients
Parallel histopathological comparative analyses of the lungs of
COVID-19 and pandemic influenza A(H1N1) patients have not
been conducted. Here, we obtained lung autopsy specimens from
individuals that succumbed to either of these diseases and
analyze their pathological features. Our analysis revealed that
pandemic influenza A(H1N1) induces alveolar edema and intra-
alveolar inflammatory infiltrates in the lungs, sparing the
integrity of alveolar walls and the micro-architecture of the
organ (Figure 2A, left panel). These findings are compatible
with a typical pattern of alveolar pneumonia. The inflammatory
infiltrates observed in the lungs of pandemic influenza A(H1N1)
patients were composed of macrophages, polymorphonuclear
cells, and scarce lymphocytes scattered between areas of intra-
alveolar edema, hemorrhage, and fibrin mucoid exudates.
Furthermore, although conserved, the alveolar walls showed
capillaries with vasodilation and congestion (Figure 2A, right
panel). Meanwhile, SARS-CoV-2 induced intense and extensive
inflammatory lung infiltrates, as well as thickness of alveolar
walls, hemorrhages, and partial loss of the histological
architecture of the lung. These changes are compatible with
interstitial pneumonia (Figure 2B, left panel). The inflammatory
infiltrates observed in the lungs of COVID-19 patients were
mainly composed of macrophages. Notably, the lungs infected
with SARS-CoV-2 showed scarce lymphocytes and detachment
TABLE 2 | Laboratory parameters of participants at admission.
Parameter Influenza A(H1N1)











Glucose (mg/dL) 132.1 (111 – 207.4) 0.1241 96.5 (85.2 – 112) 0.3025 124.3 (99 – 163.7) >0.9999
Blood count






7.3 (5.8 – 11.9)
5.7 (4.6 – 9.9)
0.7 (0.4 – 0.9)
8.4 (5.1 – 17.1)
14.2 (13 – 17.3)







4.0 (3.5 – 5.7)
2.9 (1.8 – 3.9)
0.9 (0.6 – 1.2)
3.1 (1.6 – 5.7)
15.4 (14.2 - 16.4)







9.5 (6.4 – 13.1)
7.4 (4.1 – 10.1)
0.9 (0.6 – 1.2)
8.7 (3.7 – 13.4)
13.7 (13.2 – 15.1)












1.1 (0.9 – 2.2)
22.2 (16.2 – 34.3)
135.2 (132.5 – 139.3)





1.0 (0.8 – 1.1)
14.5 (10.5 – 18.8)
137 (136 – 139)





0.9 (0.8 – 1.5)
18 (11.9 – 26.8)
139.8 (136.2 – 141.7)










0.6 (0.4 – 0.8)
60.9 (39.6 – 84.1)
29.2 (23.3 – 47.5)





0.3 (0.3 – 0.4)
22.6 (15 – 38.5)
21.7 (17.2 – 32.1)





0.5 (0.4 – 0.8)
43.5 (29 – 90.7)
40.2 (28.8 – 56.8)









643.8 (452.2 – 804.7)
274.4 (158.2 – 771.2)




186 (165.8 – 251.5)
73 (49.7 – 161.3)




414.5 (318 .4– 494.8)
160.3 (74.6 – 1419)










7.37 (7.32 – 7.45)
51 (38 – 67)
35 (30 – 48)
1.2 (0.8 – 1.5)






7.43 (7.41 – 7.46)
65 (55 – 91)
34 (29 – 37)
ND






7.41 (7.33 – 7.45)
51 (42 – 65)
34 (27 – 47)
0.9 (0.8 – 1.1)







Mild (PaO2/FiO2 201 - 300)
Moderate (PaO2/FiO2 101-200)
Severe (PaO2/FiO2 <100)
























Severity of illness scores
SOFA
APACHE II
8 (7 – 13)
11 (5 – 18)
<0.0001
0.0405
1 (0 – 2)
4 (0 – 7.5)
0.0031
0.3546
6 (3 – 8)
7 (4 – 10)
0.0398
0.6420
Data are displayed as n (%) or median (IQR). N is the total number of patients with available data. ALP, alkaline phosphatase; APACHE-II, Acute Physiology and Chronic Health Evaluation II;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood ureic nitrogen; CPK, creatine phosphokinase; Cr, creatinine; FiO2, fraction of inspired oxygen; HCO3,
bicarbonate; Hgb, hemoglobin; IQR, interquartile range; LDH, lactate dehydrogenase; ND, not determined; NLR, neutrophil/lymphocyte ration; PaO2, partial pressure of oxygen in arterial
blood; PCO2, partial pressure of carbon dioxide in the blood; SD, standard deviation; SOFA, Sequential Organ Failure Assessment. Differences in continuous variables were estimated
using the Kruskal Wallis with post hoc Dunn´s test. Differences in categorical variables were calculated using the Fisher’s exact or the Chi-square test as appropriate.
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of pneumocytes, which showed hyperplasia, cellular changes,
and prominent nucleoli (Figure 2B, right panel).
Interestingly, our IHQ analysis showed that IFN-g, IL-1b,
and IL-17A were expressed in the lungs of patients with
both diseases, mainly inside macrophages and pneumocytes
(Figure 3). However, the intensity of expression of IFN-g and
IL-17A was higher in patients infected with SARS-CoV-2.
Strikingly, IL-4, a Th2 cytokine, was absent in the lungs of
pandemic influenza A(H1N1) patients but expressed in COVID-
19 subjects (Figure 3). These findings are in line with the
combined Th1/Th2 immune profile detected only in the serum
of our cohort of patients infected with SARS-CoV-2 but not in
pandemic influenza A(H1N1) subjects.
Clinical and Immunological Markers
Distinguishing Pandemic Influenza A
(H1N1) and COVID-19
To determine which clinical and immunological characteristics
contributed more to the differences between pandemic influenza
A(H1N1) and COVID-19, we performed PCA. The analysis
showed that pandemic influenza A(H1N1) patients cluster
apart from the combined cohort of COVID-19 subjects in the
PC2 (Figure 4A). Of note, clinical characteristics contributed to
31.2% of the total variance explained by the two first PCs
(12.51% to PC1 and 50.03% to PC2). Meanwhile, serum
cytokine levels contributed to 68.7% of the total variance
explained by the two first PCs (87.48% to PC1 and 49.96% to
PC2). These data indicate that immunological characteristics
may be more useful than clinical variables to discriminate
between both diseases. Thus, we performed additional PCAs
using only clinical or immunological characteristics. We
observed that patients with severe pandemic influenza A
(H1N1) were not separated from severely ill COVID-19
patients by their clinical features, but they clustered apart from
moderate COVID-19 subjects (Supplemental Figure 3a). Age,
neutrophils, ALP, CPK, bilirubin, LDH, PaO2/FiO2, and SOFA
were the clinical variables that contribute more to the first two
PCs of this analysis. Conversely, pandemic influenza A(H1N1)
patients clustered apart from the entire COVID-19 cohort in a
PCA using only serum cytokine levels (Supplemental Figure
3b). IFN-g, IL-1RA, IL-5, IL-9, IL-10, and G-CSF levels
contribute to the first two PCs of this PCA.
Using logistic regression analyses, we further evaluated which
clinical and immune factors differentiate our two cohorts of
severely ill pandemic influenza A(H1N1) and COVID-19
patients. IFN-g was not included in this analysis, as it showed
perfect discrimination of severe COVID-19 from pandemic
influenza A(H1N1). We identified that LDH, ALP,
procalcitonin, SOFA score, IL-1RA, IL-2, IL-7, TNF-a, CCL3,
and G-CSF levels were significantly associated with severe
pandemic influenza A(H1N1). In contrast, IL-1b, IL-4, IL-5,
IL-12p70, IL-13, IL-17A, CCL11, and VEGF levels predicted
severe COVID-19 (Figures 4B, C). Some of these factors, along
with PaO2/FiO2 index, the incidence of acute kidney injury
(AKIN), co-infections, APACHE-II score, IFN-g, IL-15, and
CCL5, also contributed to differentiate the entire COVID-19
cohort from pandemic influenza A(H1N1) subjects
(Supplemental Figure 4).
An LDA showed that some of these selected parameters,
along with AST and ALT, used together, accurately differentiate
between severe pandemic influenza A(H1N1), moderate
COVID-19, and severe COVID-19 groups (Figures 5A, B).
Since it would be impractical to assess all these factors
combined to differentiate both diseases, we analyze the results
of the LDA using the Wilk´s Lambda test. This analysis showed
that ALT, ALP, SOFA, IL-2, and TNF-a were crucial for the
TABLE 3 | Complications and treatment of study participants.
Parameter Influenza
A(H1N1) pdm09 A N = 23
p-value A vs. B Moderate












































































































Renal replacement therapy 6 (26.08) 0.1445 0 (0) 0.2908 5 (20.83) 0.4252
Mortality 5 (21.73) 0.2911 0 (0) 0.0135 15 (62.5) 0.0077
Data are displayed as n (%) or median (IQR). N is the total number of patients with available data. ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; MV, mechanical
ventilation; SD, standard deviation. Differences in continuous variables were estimated using the Kruskal Wallis with post hoc Dunn´s test. Differences in categorical variables were
calculated using the Fisher’s exact or the Chi-square test as appropriate.
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discriminative power of our LDA model (Figure 5C).
Furthermore, receiver operating characteristics (ROC) curve
analyses showed that IFN-g, IL-1b, IL-12p70, G-CSF, and
VEGF had the highest diagnostic performance to distinguish
severe COVID-19 and pandemic influenza A(H1N1) (Figure 6).
Clinical and Immunological Prognostic
Factors in Pandemic Influenza A(H1N1)
and COVID-19
We also evaluated the prognostic value of clinical and
immunological factors in pandemic influenza A(H1N1) and
COVID-19. Among COVID-19 patients, the duration of
symptoms before admission, WBC, neutrophil counts, LDH,
and SOFA score predicted severe disease defined as the need
for intubation (Figure 7A). IL-4, IL-7, IL-8, IL-12p70, IL-15, and
VEGF were also associated with increased risk of intubation in
COVID-19 subjects. IL-6 showed increased but not significant
OR values for severity in the combined COVID-19 cohort,
contrasting with previous studies that indicate that IL-6 is
significantly associated with severe COVID-19 (18, 30). Using
a similar approach, we observed that WBC, and SOFA score
conferred a higher risk of death after SARS-CoV-2 infection in
the entire cohort of COVID-19 patients (Figure 7B). Likewise,
the need for renal replacement therapy (OR 32, 3 – 849.9 95% CI,
p = 0.0029), and the use of steroids (OR 25.5, 2.1 – 698.4 95% CI,
p = 0.0091), were associated with mortality risk after pandemic
influenza A(H1N1) (Supplemental Figure 5), as reported before
(31, 32). However, none of the evaluated cytokines were
associated with mortality in COVID-19 and pandemic
influenza A(H1N1) patients (Figure 7 and Supplemental
Figure 5). At the time of patient recruitment, there was no
consensus regarding the use of steroids for COVID-19, and the
RECOVERY trial had not been published (33). Hence, only some
of our COVID-19 patients were treated with steroids.
Additional Immune Markers Distinguishing
Pandemic Influenza A(H1N1)
From COVID-19
Finally, we analyzed another set of immune mediators in the
blood of 25 moderate and 24 severe COVID-19 patients, as well
as in 22 pandemic influenza A(H1N1) subjects, from which we
were able to obtain plasma samples (Figure 8 and Supplemental
Figure 6). Plasma levels of these factors showed only a few
correlations with clinical characteristics and serum cytokine
A B C D E
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FIGURE 1 | Serum cytokine levels in pandemic influenza A(H1N1) and COVID-19 patients. Serum levels of cytokines, chemokines, and growth factors in healthy
volunteer donors (HD, n=13), patients with COVID-19 (n=10 moderate, 24 severe), and influenza (n=23), were assessed by Luminex assay. Violin plots display
medians and interquartile ranges (IQR). Differences between groups we estimated using the Kruskal-Wallis test with post hoc Dunn´s test. Significant differences are
denoted by bars and asterisks: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (A) IFN-g, interferon-gamma; (B) TNF-a, tumor necrosis factor-alpha; (C) IL-1b,
interleukin 1beta; (D) IL-1RA, interleukin 1 receptor antagonist; (E) IL-2, interleukin 2; (F) IL-4, interleukin 4; (G) IL-5, interleukin 5; (H) IL-7, interleukin 7; (I) IL-12p70,
interleukin 12 p70 subunit; (J) IL-13, interleukin 13; (K) IL-17A, interleukin 17A; (L) CCL3, C-C motif chemokine ligand 3; (M) CCL11, C-C motif chemokine ligand
11; (N) G-CSF, granulocyte colony-stimulating factor; (O) VEGF, vascular endothelial growth factor.
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levels (Supplemental Figure 7). The overall profile of these
correlations was different in pandemic influenza A(H1N1) and
COVID-19 patients, suggesting distinct immune mechanisms
underlying clinical manifestations of both diseases.
Although levels of plasma type I interferons were below the
levels of reliable detection, IFN-a, and IFN-b were increased
among all participant groups as compared to healthy controls
(Figure 8). Furthermore, a slight increase in the levels of IFN-b
was noticed in pandemic influenza A(H1N1) patients as
compared to COVID-19 patients. Remarkably, although
elevated, the levels of APRIL/TNFSF13, sCD30, sCD163,
sTNF-R1, and sTNF-R2 were lower in COVID-19 than in
pandemic influenza A(H1N1) patients. APRIL/TNFSF13 is
crucial for plasma cell survival (34). Thus, plasma cell
responses could be downregulated in COVID-19 as compared
to pandemic influenza A(H1N1). Soluble CD30 has been
proposed as a marker of T cell activation during solid organ
transplant rejection (35), whereas sCD163 is a readout of
macrophage activation (36). Hence, our data may indicate a
depletion of activated lymphocytes and macrophages from the
circulation during SARS-CoV-2 infection, despite the high levels
of inflammatory mediators found in COVID-19 patients. Soluble
TNF-R1 and sTNF-R2 act as decoy receptors for TNF-a (37); as
such, patients with COVID-19 might be less capable of balancing
pathogenic TNF-a activities than individuals with pandemic
influenza A(H1N1).
TWEAK, TSLP, MMP-1, and MMP-3 were elevated in
COVID-19 cases. TWEAK is a stimulator of IL-6, IL-8,
CXCL10, and MMP-1 (38, 39). As such, high levels of TWEAK
might expand the inflammatory response observed in COVID-19
patients. TSLP is a promoter of allergic inflammation and Th2
responses (40). Indeed, high TSLP levels coincide with a Th2
cytokine profile in our COVID-19 cohort. Our results also indicate
a possible role for MMP-1 and MMP-3 in lung injury associated
with COVID-19, two matrix metalloproteases implicated in tissue
damage underlying other lung diseases (41–43).
A
B
FIGURE 2 | Histological characteristics of the lungs of patients with pandemic influenza A(H1N1) and COVID-19. Lung tissue autopsy specimens were obtained
from patients that died of pandemic influenza A(H1N1) and COVID-19. (A) The histological changes induced in the lungs during pandemic influenza A(H1N1) were
mainly characterized by intra-alveolar inflammatory infiltrates that did not compromise the integrity of alveolar walls (left panel). Meanwhile, the morphological changes
of COVID-19 consisted of extensive inflammation, thickening of the alveolar walls, and partial loss of the histological architecture (right panel). H&E staining, x100.
(B) The inflammatory infiltrates observed in the lungs of pandemic influenza A(H1N1) patients consisted of macrophages, polymorphonuclear cells, and scarce
lymphocytes scattered between areas of edema, hemorrhage, and fibrin deposits. Also, congestive, and vasodilated capillaries (arrow) were observed in the alveolar
walls of influenza patients (left panel). Conversely, the inflammatory infiltrates found in the lung of COVID-19 patients were dominated by macrophages. Furthermore,
the detachment of alveolar epithelial cells, which showed atypical characteristics such as large nucleoli (arrow), was also notable in COVID-19 patients (right panel).
H&E staining, x400.
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DISCUSSION
The ongoing winter in the Northern hemisphere has been one
of the most challenging public health crises in recent history
due to the convergence of influenza and COVID-19. This
situation could be further aggravated at settings of high
pandemic influenza A(H1N1) circulation. Thus, a better
understanding of the clinical and immunopathological
characteristics that differentiate both diseases is still required
to guide specific therapeutic approaches. This includes the
selection of adequate antiviral drugs and appropriate
immunological therapeutics for each case. Unfortunately,
FIGURE 3 | Expression of immune markers in the lungs of pandemic influenza A(H1N1) and COVID-19 patients. Expression of different immune markers in lung
autopsy specimens from pandemic influenza A(H1N1) and COVID-19 patients was assessed using specific antibodies by immunohistochemistry (IHQ), x400.
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whereas our knowledge of the immunopathogenesis of
pandemic influenza A(H1N1) has improved over the last
decade, the current lack of understanding of the COVID-19
pathobiology remains incomplete. This is a barrier to the
identification of targets for drug and vaccine development.
The inevitable co-circulation of influenza viruses and SARS-
CoV-2 and the potential scenarios of viral co-infection may
further represent an aggravation of the COVID-19 morbidity
and mortality. However, we do not know if an infection with
SARS-CoV-2 in patients already infected with influenza viruses
would result in worse or better clinical outcomes. The outcomes
of the opposite scenario are also speculative. Despite this, it is
essential to have reliable indicators to differentiate these
conditions, especially in settings of limited resources to
perform RT-PCR tests.
Some recent literature reviews have tried to highlight
differences between patients infected with SARS-CoV-2 and
seasonal influenza viruses (14, 15). However, these retrospective
comparisons carry the risk of biased conclusions due to differences
in the genetic background, sociocultural characteristics, and access
to medical attention of populations from different regions. Thus,
parallel comparisons of influenza and COVID-19 cases in
geographical settings with similar health care resources would
provide a better perspective of the main differences between these
entities. In this context, Mexico is an ideal place to conduct
comparative studies between pandemic influenza A(H1N1) and
COVID-19, as this country was the site of origin of the influenza
A(H1N1) pdm09 virus (2–4). Since its emergence in 2009,
hospitals around Mexico have acquired ample experience in the
management of severe cases of this viral infection, which has
resulted in progressive decreases in mortality rates over the last ten
years (44). On February 28th, 2020, Mexico confirmed its first two
cases of SARS-CoV-2. Ever since, the epidemiological curve of
COVID-19 shows a continuous increase in the number of positive
cases, with more than 2.2 million cases and 207,000 deaths
reported on March 2nd of 2021 (45).
Here, we compared the clinical, histopathological, and
immune characteristics of pandemic influenza A(H1N1) and
COVID-19 patients. One of the most striking findings of our
study was that most of the clinical and laboratory parameters
routinely evaluated in emergency departments were similar
between both infections in severe disease. Nonetheless, some
A B
C
FIGURE 4 | Clinical and immunological factors that distinguish pandemic influenza A(H1N1) and severe COVID-19. (A) Principal component analysis (PCA) of the
clinical and immunological characteristics of study participants. Each dot represents a single individual, and each color represents a group of participants: blue for
pandemic influenza A(H1N1), orange for moderate COVID-19, and red for severe COVID-19. (B, C) Bivariate logistic regression analysis of the clinical and
immunological characteristics associated with the causative pathogen in the two cohorts of patients with severe influenza and COVID-19. The forest plots show the
odds ratio (OR) and 95% CI interval values that were non-significant (black) and significant for severe COVID-19 (red). OR values of factors inversely associated with
severe COVID-19 that instead predict pandemic influenza A(H1N1) are shown in blue color. Absolute OR values are also presented in Supplementary Table 3.
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features separated well moderate COVID-19 patients from
severe COVID-19 and pandemic influenza A(H1N1) subjects.
Interestingly, our data reveal that respiratory symptoms are more
common during pandemic influenza A(H1N1), whereas dry
cough and gastrointestinal symptoms are distinctive
characteristics associated with COVID-19. These clinical
differences may traduce distinct infective capacities of both
viruses to affect several organs besides the lungs. In this sense,
influenza viruses are thought to be primary respiratory
pathogens that rarely cause extrapulmonary dissemination
(46). Meanwhile, it is accepted that SARS-CoV-2 has a broad
infective capacity to invade several tissues and organs (47). The
expression of the angiotensin I converting enzyme 2 (ACE2), the
transmembrane serine protease 2 (TMPRSS2), furin, cathepsin L,
and other viral entry factors in human organs determine the
tissue tropism of SARS-CoV-2. These factors are expressed in the
lungs; nonetheless, their expression is even higher at several parts
of the upper and lower gastrointestinal tract (48). This might
explain the clinical differences observed in our study.
We also found that levels of ALP, ALT, LDH, CPK,
procalcitonin, as well as SOFA and APACHE II scores were
higher in pandemic influenza A(H1N1) as compared to both
groups of COVID-19 patients. Meanwhile, the PaO2/FiO2 upon
arrival was similar in severe COVID-19 and severe pandemic
influenza A(H1N1) patients. These findings coincide with the
results of a previous study evaluating the differences in clinical
presentations between Chinese ARDS patients infected with
either SARS-CoV-2 or influenza A(H1N1) (13). The
researchers also found that ground-glass opacities were more
common in radiological studies of COVID-19 patients, whereas
consolidation opacities were more frequent in influenza subjects.
Ground-glass opacities are typically associated with an
interstitial inflammatory process of the lung, whereas
consolidations traduce intra-alveolar exudates (49). Here, we
found that the histopathological pattern induced after lung
infection with SARS-CoV-2 is mainly characterized by an
interstitial inflammatory infiltrate. Meanwhile, pandemic
influenza A(H1N1) induces changes compatible with alveolar
pneumonia. Together, both studies highlight that the two
diseases display crucial differences in the histological




FIGURE 5 | Selected clinical and immunological characteristics that better distinguish pandemic influenza A(H1N1) from COVID-19. (A) Linear discriminant analysis
(LDA) plot of the first two discriminant functions showing the separation of the different groups of study participants according to a set of selected clinical and
immunological characteristics used in combination. Each dot represents a single individual, and each color represents a group of participants: blue for pandemic
influenza A(H1N1), orange for moderate COVID-19, and red for severe COVID-19. (B) Accuracy of the LDA results before and after a “leave-one-out” cross-
validation. (C) The discriminant potential of each individual variable included in the LDA was estimated using the Wilk´s Lambda test. The table displays values of
Wilk´s lambda, F, and p for each variable.
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The immune response against SARS-CoV-2 is not well
comprehended so far. The prevailing paradigm to explain the
morbidity and mortality of COVID-19 patients is that SARS-
CoV-2 elicits an exuberant immune reaction characterized by a
dysregulated cytokine production. This phenomenon, known as
“cytokine storm,” is thought to be responsible for mediating
tissue injury in patients with COVID-19 that progress to severe
illness (19, 28, 50, 51). The immune receptors that recognize the
viral infection and initiate the immune responses against SARS-
CoV-2 are unknown. As this virus is genetically related to SARS-
CoV-1, it is presumed that both viruses share mechanisms of
infection. In this sense, SARS-CoV-1 is recognized by the toll-
like receptors (TLR) TLR3 and TLR4, which induce an immune
reaction via MyD88 and TRIF pathways (52, 53). Furthermore,
SARS-CoV-1 triggers the production of IL-1b through the
activation of the inflammasome (54). It is also possible that
SARS-CoV-2 activates the inflammasome, as high levels of IL-1b
have been observed in COVID-19 patients (55). Other immune
mediators exaggeratedly produced in response to SARS-CoV-2
include IL2, IL-6, IL7, IL10, G-SCF, CXCL10, CCL2, CCL3, and
TNF-a (9, 17, 28). Similar immune signatures were detected in
our cohort of COVID-19 patients. Strikingly, our study, and two
recent investigations carrying out single cell RNA sequencing of
immune cells and cytokine determinations in BAL (16, 56),
converge in a major pathogenic role of IL-1 b, IL-6, and CCL2
in patients who develop severe COVID-19 compared to people
with less severe disease.
Meanwhile, the pathogenicity and virulence of the influenza
A(H1N1) pdm09 virus are due to acquired properties
contributing to alter the regulation of inflammatory responses
FIGURE 6 | Diagnostic value of the clinical and immunological factors that distinguish between severe COVID-19 and pandemic influenza A(H1N1). Receiver
operating characteristic (ROC) curves were constructed for the clinical and immunological characteristics that showed significant OR values in the bivariate logistic
regression analysis. ROC curves of variables associated with pandemic influenza A(H1N1) are shown in blue color, whereas variables associated with severe COVID-
19 are displayed in red color. The graphs show area under the curve (AUC) and 95% CI interval values.
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and evade antiviral immunity. Previously, we have described that
pandemic, but not seasonal influenza A strains, downregulate the
expression of the suppressors of cytokine signaling 1 (SOCS-1)
and increase the production of IL-6, IL-8, TNF-a, IL-10, CCL3,
CCL4, and CCL5 in experimental infection assays of human
lung A549 epithelial cells and human macrophages (57). Levels
of IL-6, IL-8, TNF-a, and CCL3 were also increased in our
cohort of pandemic influenza A(H1N1) patients, validating
our previous observations. The influenza A(H1N1) pdm09 also
suppresses the expression of the retinoid-inducible gene I (RIG-
I) and induces lower levels of type I interferons in human
macrophages and human lung epithelial cells, as compared to
seasonal influenza A strains (57). In this sense, it is possible that
blocking type I interferon responses might be a strategy of SARS-
CoV-2 to evade antiviral immune mechanisms, as we found very
low induction of plasma IFN-a and IFN-b in both pandemic
influenza A(H1N1) and COVID-19 patients. A similar type I
interferon deficiency was observed in the blood of French
critically ill COVID-19 patients (58). Conversely, another
study from Korea reveals that type I interferon expression is
increased in BAL immune cells from severe COVID-19 patients
(16), indicating that antiviral interferon responses against SARS-
CoV-2 might be highly compartmentalized into the lungs and
barely detectable in the blood.
Notably, despite the dysregulated production of other
immune mediators, an ample range of immune cell subtypes
are depleted from the circulation of patients with severe SARS-
CoV-2 infection. These cells include monocytes, dendritic cells,
CD4+ T cells, CD8+ T cells, B cells, and NK cells (59).
Furthermore, the few adaptive lymphocytes that remain in the
blood express markers of functional exhaustion (29). These data
suggest that severe COVID-19 is a state of immunosuppression
A
B
FIGURE 7 | Clinical and immunological factors associated with disease outcomes in patients with COVID-19. (A) Bivariate logistic regression analysis of the clinical
and immunological characteristics associated with intubation in patients COVID-19. (B) Clinical and immunological factors associated with mortality in patients with
COVID-19. The forest plots show the odds ratio (OR) and 95% CI interval values. OR values that did not include the null value in the 95% CI were considered
significant for intubation/mortality and are shown in red color. Absolute OR values are also presented in Supplemental Table 5.
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similar to the known sepsis‐induced immunosuppression (60).
Notably, a recent study by Remy and collaborators has shown
that the immunosuppression observed in COVID-19 is even
more profound than in critically ill patients with sepsis of other
causes (27). These researchers demonstrated that the production
of IFN-g by peripheral blood T cells of COVID-19 patients was
impaired as compared with T cells from healthy individuals and
septic patients after anti-CD3/anti-CD28 antibody stimulation.
Furthermore, a reduced production of TNF-a by stimulated
monocytes from COVID-19 patients was noticed. These findings
led the researchers to propose that the primary immune
mechanism underlying the morbidity and mortality of COVID-
19 is immunosuppression rather than hyperinflammation.
In this context, our study confirms that the immune response
against SARS-CoV-2 is entirely different from the response
against pandemic influenza A(H1N1). Indeed, our analyses
bring forward a set of immunological markers with the
potential to differentiate COVID-19 from pandemic influenza
A(H1N1) successfully. Measuring some of these markers might
improve the diagnostic approach and subsequent therapeutic
decision for ARDS patients. Also, our study may provide
additional evidence useful to clarify current controversies
about the immunopathology of COVID-19. Based on our
results and previous investigations, we propose that
hyperinflammation and immunosuppression are not mutually
exclusive in COVID-19. First, our data showed some indirect
readouts of immunosuppression in individuals infected with
SARS-CoV-2. For instance, we found that TNF-a levels were
lower in the serum of COVID-19 patients as compared to
pandemic influenza A(H1N1) patients. This coincides with the
limited capacity of monocytes from COVID-19 patients to
produce TNF-a upon stimulation described by Remy et al.
(27). We also observed lower plasma levels of the macrophage
activation marker sCD163, although macrophages infiltrating




FIGURE 8 | Immune mediators in the plasma of patients with pandemic influenza A(H1N1) and COVID-19. Levels of different soluble immune mediators in plasma
samples from patients with COVID-19 (n=25 moderate, 24 severe) and pandemic influenza A(H1N1) (n=23), as well as in samples from healthy volunteer donors (HD,
n=4) were assessed by Luminex assay. Violin plots display medians and interquartile ranges (IQR). Differences between groups we estimated using the Kruskal-Wallis
test with post hoc Dunn´s test. Significant differences are denoted by bars and asterisks: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (A) IFN-a, interferon-
alpha; (B) IFN-b, interferon-beta; (C) TWEAK/TNFSF12, tumor necrosis factor-like weak inducer of apoptosis/tumor necrosis factor ligand superfamily member 12;
(D) APRIL/TNFSF13, A proliferation-inducing ligand/tumor necrosis factor ligand superfamily member 13; (E) sCD30/TNFRSF8, soluble CD30/tumor necrosis factor
ligand superfamily member 8; (F) sCD163, soluble CD163; (G) sTNF-R1, soluble tumor necrosis factor receptor 1; (H) sTNF-R2, soluble tumor necrosis factor
receptor 2; (I) TSLP, thymic stromal lymphopoietin; (J) MMP-1, metalloprotease 1; (K) MMP-3, metalloprotease 3.
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the lungs of COVID-19 patients expressed several cytokines.
Furthermore, we found low levels of IL-2 and APRIL/TNFSF13
(two immune mediators crucial for T-cell and plasma cell
survival), as well as sCD30 (a marker of lymphocyte
activation) in the circulation of COVID-19 but not pandemic
influenza A(H1N1) patients. Similarly, we observed a lack of
lymphocytes in the inflammatory infiltrates found in lung
autopsy specimens from patients that died of COVID-19.
These findings may reflect a depletion of activated lymphocytes
and monocytes from the circulation during SARS-CoV-2
infection and poor recruitment of lymphocytes to the lungs.
At the same time, we have described that an exacerbated
polyfunctional immune response prevails in the circulation of
COVID-19 patients. Such a response is characterized by higher
levels of Th1 as well as Th2 cytokines as compared to pandemic
influenza A(H1N1) patients. Conversely, although pandemic
influenza A(H1N1) subjects also display elevated levels of some
inflammatory mediators, these individuals may have enough
regulatory mechanisms that counteract the detrimental effects of
hyperinflammation. The higher levels of IL-1RA observed here in
pandemic influenza A(H1N1) patients as compared to COVID-19
subjects well exemplify this. Furthermore, we found higher serum
levels of the C-X-C motif chemokine ligand 17 (CXCL17), a
mucosal chemokine with anti-inflammatory properties, in
pandemic influenza A(H1N1) but not COVID-19 patients (61).
In addition, the serum cytokine pattern of COVID-19 resembles the
inflammatory profile of rheumatoid arthritis patients with
interstitial lung disease (62), and the polyfunctional inflammatory
response of the cytokine release syndrome (CRS) that occurs after
chimeric antigen receptor (CAR) T-cell therapy (63).
Immunosuppression and hyperinflammation are also a hallmark
of both of these conditions.
Of note, the higher levels of Th2 cytokines, particularly IL-4 and
IL-5, might inhibit Th1 protective antiviral responses in COVID-19
patients. Thus, our data indicate that a lack of immune balance of
the type of effector response is another crucial determinant of the
collapse of the host protective immunity against SARS-CoV-2. This
Th2 biased response may generate interstitial infiltrates of Th2
cells, neutrophils, eosinophils, and type 2 innate lymphoid cells,
mediating lung inflammation, and tissue damage. In fact, critically
ill COVID-19 patients usually show interstitial lung infiltrates,
some of which resemble several forms of progressive interstitial
lung disease like cryptogenic organizing pneumonia and non-
specific interstitial pneumonia (9, 64–66). Here, we also observed
interstitial inflammation and expression of IL-4 in the lungs of
COVID-19 patients but not pandemic influenza A(H1N1) subjects.
These deleterious effects of Th2 responses could also explain the
abnormalities in lung function, and progression to pulmonary
fibrosis observed in more than 45% of COVID-19 patients
discharged from hospitals (67), particularly in older patients.
Hence, it would be of great interest to characterize the cytokine
profile of COVID-19 patients that subsequently develop any form
of interstitial lung disease, as they would benefit from specific and
anti-fibrotic therapeutics.
We propose that ideal immune therapeutics for COVID-19
should be directed not only to blocking or enhancing specific
immune signaling pathways to counteract hyperinflammation or
reverting immunosuppression. Instead, immune therapies must
re-establish a convenient immune balance that promotes
protective immunity against SARS-CoV-2. Under the light of
this hypothesis, several immune mediators and immune cell
subsets could be targeted. For instance, type 2 innate lymphoid
cells (ILC2s) have been identified as the leading producers of Th2
cytokines in the lungs, contributing to potent allergen-induced
airway inflammation even in lymphopenic hosts (68). Thus,
ILC2s may constitute novel targets to inhibit Th2 responses in
COVID-19 patients. The potential pathogenic effects of Th2-
biased responses in COVID-19 may also be counteracted with
monoclonal antibodies. For instance, dupilumab, a monoclonal
antibody against IL-4, has been safely used in patients with atopic
dermatitis and COVID-19, without increased risk of severe
complications of the infection. Remarkably, some patients
receiving dupilumab that later acquired the infection with
SARS-CoV-2 did not show respiratory symptoms (69–71).
Finally, TSLP could be another target to inhibit Th2 responses
in COVID-19 patients, as this molecule promotes allergic
inflammation (40), and indeed, high levels of TSLP were
observed in our cohort of COVID-19 but not pandemic
influenza A(H1N1) subjects.
LIMITATIONS
A limitation of our study is that we did not recruit patients
infected with seasonal influenza virus subtypes. Thus, our
observations are only useful to distinguish between influenza A
(H1N1) pdm09 and SARS-CoV-2 infection. The clinical and
immunological characteristics of SARS-CoV-2 and seasonal
influenza have been compared in a recent study by Mudd et al.
(72). In such a study, researchers found that COVID-19, as
compared to seasonal influenza, is characterized by lower mean
cytokine levels in serum. Conversely, we found that cytokine
levels were higher in COVID-19 patients than in individuals with
pandemic influenza A(H1N1). These discrepancies are probably
related to variations in the virulence and capacity to induce
inflammatory immune responses of seasonal and pandemic
influenza viruses. Lee et al. (16), also compared single cell
RNA sequencing of BAL immune cells from COVID-19 and
influenza A patients. Although these researchers did not specify
the subtype of influenza A virus infection, their results coincide
with our data with regards to the higher induction of IL-1b in
COVID-19 than influenza. However, differential roles of TNF
and type I interferon signaling during the two diseases are
important discrepancies between their and our study. The
source and time of sample collection can potentially be a
reason for these differences. Finally, another limitation of our
study is that we did not measure cytokine levels in serial serum/
plasma samples from our two cohorts of pandemic influenza A
(H1N1) and COVID-19 patients. Thus, future investigations
should compare differences in the kinetics of immune
responses against both diseases. Despite this, our study
provides important insights into the differences between the
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two most important respiratory pathogens that have caused
pandemics of international concern in recent years.
CONCLUSIONS
In conclusion, our results demonstrate significant differences
in the immune responses elicited after SARS-CoV-2 and
influenza A(H1N1) pdm09 virus. Our data support the use of
specific clinical characteristics, laboratory parameters, and
immunological markers to differentiate SARS-CoV-2 infection
from pandemic influenza A(H1N1). These data may also
contribute to the discovery of novel therapeutic targets to
counteract harmful immune mechanisms underlying the
immunopathology of COVID-19 and pandemic influenza
A(H1N1).
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